HeartFlow’s AI-enabled plaque quantification technology has been upgraded to a new I CPT category code by the American Medical Association.

For patients with type 2 diabetes mellitus (T2DM), glucagon-like peptide 1 receptor agonist (GLP-1 RA) use is associated with a lower risk for venous thromboembolism (VTE).

Individuals with primary biliary cholangitis and diabetes may experience worse outcomes, such as progression to end-stage liver disease.

Continuous moderate-level maternal psychological distress throughout pregnancy is associated with a heightened risk for epilepsy among offspring.

Diabetic hypoglycemia occurs when a person's blood sugar level falls too low. Symptoms can include: shakiness, confusion or ...

A large study suggests that, across the most populous US states, few physicians are disciplined for spreading medical ...

Detailed results were announced from the phase 3 SUMMIT trial evaluating the use of tirzepatide in adults with HFpEF and obesity.

GLP-1RA prescription trends, real-world effectiveness, and predictors for access and rationing were highlighted at ...

The increased risks for arterial thrombotic events (ATE), venous thromboembolism (VTE), and all-cause mortality known to be found among patients with systemic lupus erythematosus (SLE) were validated ...

GLP-1RA medications in preadolescents and adolescents were concentrated among those with diabetes, obesity, mood disorders, and anxiety.

Many individuals with sickle cell anemia undergoing controlled ovarian hyperstimulation (COH) with oocyte cryopreservation (OC) have complications.

Mortality risk, especially due to dermatological and endocrine causes, was higher among patients with type 1 diabetes compared with type 2 diabetes.